Deutsch
Englisch
NOAH:
Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes
PATIENTS
End of patient enrollment
08.09.2022
2666 patients enrolled
(2613 patients randomised, 2545 patients randomised and treated)
Status as of 8th of September 2022
2538
Planned number of participants
0 randomised and treated patients pending to archieve recruitment target
PARTICIPATING COUNTRIES
18 european countries:
Belgium, Bulgaria, Germany, Denmark, France, Greece, United Kingdom, Italy, The Netherlands, Austria, Poland, Portugal, Romania, Sweden, Spain, Czech Republic, Ukraine, Hungary
PUBLICATIONS
Bertaglia E, Blank B, Blomstrom-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, deGroot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, and Kirchhof P. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace. 2019; 0, 1–9.
doi: 10.1093/europace/euz172
Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, Chlouverakis G, Diener HC, Kirchhof P. Atrial high-rate episodes and stroke prevention. Europace. 2017 Feb 1;19(2):169-179. doi: 10.1093/europace/euw279. Epub 2016 Feb 29.
Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.
Sponsor
Atrial Fibrillation NETwork (AFNET), Münster, Germany
Scientific leader
International Chief Investigator:
Prof. Paulus Kirchhof, Hamburg, Germany